ifa systems AG
- WKN: 783078
- ISIN: DE0007830788
- Land: Deutschland
Nachricht vom 16.04.2019 | 07:59
ifa systems successfully completed the financial year 2018
DGAP-News: ifa systems AG / Key word(s): Annual Results/Forecast
ifa systems successfully completed the financial year 2018
The ifa systems AG, a listed specialist for Health-IT applications in ophthalmology, has achieved its revenue and result targets in the financial year 2018. The revenue in the ifa Group amounted to EUR 6.6 million (previous year: EUR 8.6 million). The significant decrease was in connection with the completed major projects in 2017 (EUR 2.3 million). Adjusted for this effect, growth (2.1 percent) in the core business was successfully generated in the past financial year. After completing the restructuring process and the strategic reorientation, the operating result (EBIT) with EUR 106 thousand also returned to be positive (previous year: EUR -7.8 million).
"Thus, the adjustments have proved to be successful and appropriate", says Jörg Polis, chairman of the Management Board of ifa systems AG. "We expect that profitability will also further improve in accordance with the business development in the future."
Revenue growth in the core business
As expected, the concentration on the core business in the financial year 2018 led to significant changes in revenue in some product groups. The revenues of the basic licenses increased by 28 percent; they result from the first sale of products. The revenues from hardware, third-party software and accessories also increased significantly by 24.6 percent. Here, the successful implementation of third-party software is reflected. In return, the project business with Topcon reduced close to zero as expected. The major projects were already completed in the financial year 2017.
Strong improvement in results by rightsizing
The calculated cost reductions in accordance with the low revenue had considerably positive effects on the result. The volume of the purchased goods and services reduced by 30.5 percent to EUR 604 thousand (previous year: EUR 869 thousand), especially due to low development costs provided by third parties. Also, the staff costs decreased by almost one-third. They amounted to EUR 3.5 million in the financial year 2018 (previous year: EUR 4.9 million). Other operating expenses reduced to EUR 2.5 million and thus to a level that can also be expected for the future. The previous year's figure was affected in the amount of EUR 1.9 million i.a. by expenses for restructuring and other one-time effects
In total, a consolidated net income of EUR 740 thousand (Previous year: EUR -9.3 million) was generated in the financial year 2018 corresponding to a result of EUR 0.27 per shares outstanding (previous year: EUR -3.38) Given the fact that the free cash flow is still negative for 2018 (EUR -606 thousand), the Management Board once again suggests distributing no dividends for the year 2018.
Outlook 2019 Revenue growth and significant improvement in results
The figures of the past financial year show that the ifa Group has strategically repositioned itself and emerged strengthened from the restructuring. The Management Board is confident that the positive development will also continue in the financial year 2019.
The ifa Group expects a slight growth in revenue to EUR 6.8 million and up to EUR 7.2 million. The highest growth rate shall be contributed by ifa systems AG which will benefit especially in the first half-year from the installations of the telematics infrastructure (TI). "The TI provides a good opportunity to further expand the installed customer base and equip them with complementary solutions", says Mr. Polis. "The Electronic Medical Record, as core element of our integration platform, will significantly gain in importance in the next years due to the implementation of TI.
The operating result (EBIT) shall significantly improve further in the financial year 2019. Depending on the revenue performance, it is planned with a volume between EUR 0.2 and 0.5 million, which would correspond on average to an EBIT margin of approximately 5 percent. Furthermore, a positive operating cash flow shall again be generated in 2019, which was still burdened by the restructuring in the financial year 2018.
"The sustained stabilization of the business situation in the second half of 2018 has led to utilize ifa system AG's financial resources to reduce external debts step by step", says Polis. In the first quarter of 2019, a part of the loan at the Mizuho Bank has already been returned.
Annual General Meeting on June 7, 2019
At this year's Annual General Meeting, besides the common proposed resolutions, the possibility of repurchasing shares shall be put to the vote as well. The Management Board and the Supervisory Board request permission to use this instrument over the period until 2024 if required.
Contact for questions:
The ifa systems AG is listed on the open market at the German Stock Exchange under ISIN: DE 007830788. The Topcon Corp., a Japanese Technology company, holds more than 50.1 % shares through the subsidiary Topcon Europe Medical B.V. and is also noted (Japanese Stock Exchange Tokyo 7732 TYO).
Key figures table for 12/31/2018
|Company:||ifa systems AG|
|Augustinusstraße 11 b|
|Phone:||+49 (0)2234 93367-0|
|Fax:||+49 (0)2234 93367-30|
|Listed:||Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||800343|
|End of News||DGAP News Service|
Doctolib und ifa systems AG vereinbaren Kooper ...
ifa systems AG: ifa systems with strong first ...
Major order for subsidiary of ifa systems AG
Subsidiary of ifa systems AG enters into datab ...
Annual General Meeting of ifa systems AG
Anleihe im Fokus
„Semper idem Underberg AG: Emission neuer Unternehmensanleihe 2019/2025“
- Emissionsvolumen: bis zu 60 Mio. Euro
- Anleihenumtausch: 23.010. bis 06.11.2019
- Neuzeichnung: 07.11. bis 12.11.2019
- ISIN: DE000A2YPAJ3 / WKN: A2YPAJ
- Stückelung / Mindestanlage: 1.000 Euro
- Zinssatz (Kupon):
Liegt in einer Spanne von 4,00 % bis 4,25 % p.a.
- Laufzeit: 6 Jahre
- Zinszahlung: jährlich, jeweils am 18. November (nachträglich), erstmals am 18. November 2020
- Rückzahlungskurs: 100%
- Fälligkeit: 18. November 2025
- Listing: Listing im Freiverkehr (Open Market) der Frankfurter Wertpapierbörse vorgesehen
Expedeon AG mit attraktiver Produktpipeline
Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.
Der AKTIONÄR News
23. Oktober 20:17 Elon Musk liefert: Tesla macht Gewinn! Aktie legt neun Prozent zu. ...
23. Oktober 20:00 Kaufsignale ohne Ende: Mit diesen 10 Aktien starten Sie jetzt durch!
23. Oktober 16:24 Alibaba: 100-Millionen-Rekord im Visier
23. Oktober 15:15 Microsoft vor den Zahlen
23. Oktober 14:48 Nordex: Ein starkes Zeichen der Bullen
News im Fokus
Linde acquires minority stake in ITM Power and agrees joint venture
23. Oktober 2019, 12:00
Original-Research: GBC Insider Focus Index (von GBC AG): GBC Insider Focus Index
23. Oktober 2019